Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News
Widespread liver disease missed in patients with T2D
New evidence showing how common fatty liver disease and fibrosis are in patients with type 2 diabetes triggers a broadened “call to action.”
News
Cardiometabolic Center Alliance promotes multiorgan, integrated T2D treatment
Begun in 2020, the Cardiometabolic Center Alliance seeks to transform preventive care for patients with T2D with an aggressive, multidisciplinary...
News
Sotagliflozin’s trial data receives FDA welcome for NDA filing
The SOLOIST and SCORED trials of the SGLT1/2 inhibitor sotagliflozin did not proceed as planned, but the FDA says it will accept the results in an...
News
Far too few with treatment-resistant hypertension get hormone test
“Testing rates also did not change meaningfully over nearly 2 decades ... despite an increasing number of guidelines recommending testing for...
News
Twincretin ‘impressive’: Topline data from phase 3 trial in diabetes
Tirzepatide, the first dual GIP and GLP-1 receptor agonist in advanced testing, showed potent antihyperglycemic and weight loss effects in the...
News
Obesity phenotyping matches patients with more effective interventions
A prospective, randomized study suggests obesity phenotyping can guide selection of more effective, tailored weight-loss drug regimens.
Article
Finerenone’s heart benefits hold up in T2D patients without CVD
In the FIDELIO-DKD trial, cardiovascular benefits from a nonsteroidal mineralocorticoid antagonist held, regardless of CVD history, in T2D...
News
First SGLT1/2 inhibitor shows ‘spectacular’ phase 3 safety and efficacy in T2D
A pair of pivotal trials showed safety and efficacy for sotagliflozin for patients with type 2 diabetes, including novel benefits from an SGLT...
News
VTEs tied to immune checkpoint inhibitor cancer treatment
Retrospective analysis hints that cancer patients have an elevated risk for venous thromboembolism following treatment with an immune checkpoint...
News
Evinacumab, novel lipid-lowerer, extends promise in phase 2 results
Evinacumab cuts LDL-C and triglycerides by boosting lipase activity. It showed safety and efficacy in patients with heterozygous FH.
News
Empagliflozin favorably reshaped left ventricles in HFrEF patients
Results from two separate randomized studies showed empagliflozin treatment of patients with HFrEF produced significant heart remodeling.
News
New eGFR equation ‘less biased’ by age, kidney function; some disagree
The European Kidney Function Consortium equation surpasses existing equations by "resulting in generally lower bias across the spectrum of age and...
